share_log

Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome

Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome

Nova Mentis宣佈加拿大首個針對脆性X綜合徵的迷幻藥臨床試驗正在進行參與者篩查
newsfile ·  2023/08/30 20:30

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to provide an update on its Phase IIA clinical trial testing psilocybin for the treatment of fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (ASD).

溫哥華,不列顛哥倫比亞省-(Newsfile Corp.-2023年8月30日)-Nova Mentis生命科學公司(CSE:NOVA)(FSE:HN3Q)(OTCQB:NMLSF)(“Nova”或“公司”),一家生物技術公司和一流的基於裸蓋菇素的神經炎性疾病治療和補充診斷方面的全球領先企業很高興地提供了其測試裸蓋菇素治療脆性X綜合徵(FXS)的IIA期臨床試驗的最新情況。FXS是導致自閉症譜系障礙(ASD)的主要遺傳原因。

The research team is continuing its recruitment efforts and has now begun prescreening a number of potential participants with a FXS diagnosis to determine if they are eligible to join the clinical trial. Through advertising efforts across Ontario, Canada and connecting with ASD and FXS support groups, work is underway to create a registry of trial participants.

研究小組正在繼續招募工作,現在已經開始對一些被診斷為FXS的潛在參與者進行預篩選,以確定他們是否有資格參加臨床試驗。通過在加拿大安大略省的廣告宣傳以及與ASD和FXS支持團體的聯繫,正在努力創建試驗參與者的登記。

"A tremendous amount of groundwork has taken place since NOVA received Health Canada approval to conduct a human trial testing the efficacy of psilocybin on adults diagnosed with fragile X. We are very eager to enroll our first participants in this groundbreaking study, which we anticipate will happen later in September," stated Will Rascan, NOVA's President & CEO.

Nova首席執行官總裁兼首席執行官威爾·拉斯坎表示:“自從Nova獲得加拿大衛生部批准進行人體試驗,測試裸蓋菇素在被診斷為脆性X的成年人身上的療效以來,已經進行了大量的基礎工作。我們非常渴望招募我們的第一批參與者參加這項開創性的研究,我們預計這項研究將於9月晚些時候進行。”

The 28-day study will evaluate the safety and efficacy of NOVA's proprietary microdose psilocybin formulation on adult patients diagnosed with FXS, and is one of the first Health Canada approved studies allowing participants to take home psilocybin for dosing every other day. NOVA has completed production of pharmaceutical grade cGMP synthetic psilocybin 1.5 mg microdose capsules that will be used in the study.

這項為期28天的研究將評估Nova專有的微劑量裸蓋菇素製劑對被診斷為FXS的成年患者的安全性和有效性,這是加拿大衛生部批准的首批允許參與者每隔一天將裸蓋菇素帶回家服藥的研究之一。Nova公司已經完成了藥用級cGMP合成裸蓋菇素1.5 mg微劑量膠囊的生產,該膠囊將用於研究。

NOVA and KGK Science have partnered to conduct the Phase IIA clinical trial, which is being carried out at the KGK facility in London, Ontario, Canada. This 10-person, open-label study will assess repetitive, oral low-dose psilocybin therapy for FXS. The Company intends to confirm changes in behavioural symptoms with state-of-the-art diagnostic and therapeutic mRNA and serotonin biomarker technology, combined with machine learning artificial intelligence (AI).

Nova和KGK Science已經合作進行IIA期臨床試驗,該試驗正在加拿大安大略省倫敦市的KGK設施進行。這項10人的開放研究將評估重複的口服小劑量裸蓋菇素治療FXS。該公司打算利用最先進的診斷和治療信使核糖核酸和5-羥色胺生物標記物技術,結合機器學習人工智慧(AI)來確認行為癥狀的變化。

The Company anticipates treating the 10 participants in Q3/Q4 2023 and having preliminary results ready early in 2024.

該公司預計在2023年第三季度/第四季度治療這10名參與者,並在2024年初準備好初步結果。

For more information, please click here.

有關更多資訊,請單擊此處。

To express your interest in participating in this study, please complete this eligibility questionnaire.

為了表達您對參與這項研究的興趣,請填寫這份資格問卷。

If you have questions, email participate@kgkscience.com or call 1-833-858-8359.

如果您有問題,請發送電子郵件至Participate@kgkcerence.com或致電1-833-858-8359。

About Nova Mentis Life Science Corp.

關於Nova Mentis生命科學公司

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).

Nova Mentis生命科學公司是一家總部位於加拿大的生物技術公司,在開發神經炎性疾病的診斷和基於裸蓋菇素的療法方面處於全球領先地位。Nova是第一家在美國和歐盟獲得使用裸蓋菇素治療脆性X綜合徵(FXS)的孤兒藥物指定的生物技術公司。

NOVA's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.

Nova的目標是診斷和治療尚未滿足醫療需求的令人衰弱的慢性疾病,如自閉症譜系障礙(ASD)和FXS。

For further information on the Company, please visit or email info@novamentis.ca.

欲瞭解更多有關公司的資訊,請訪問或發送電子郵件至info@novamentis.ca。

About KGK Science

關於KGK Science

KGK Science is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK's other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database, and collected 10 million data points. For additional information, please visit .

KGK Science是一家北美領先的合同研究機構,總部設在安大略省倫敦市,主要提供高質量的臨床研究試驗,重點是營養食品和新興保健產品。該公司成立於1997年,已成功幫助數百家公司進行了定製設計的臨床試驗和聲稱的證實戰略,以將產品推向全球市場。KGK的其他現有服務包括專家監管支持和合規解決方案、參與者招聘、研究支持服務和諮詢服務。此外,該公司已經出版了150多份出版物,執行了40多個適應症的400多項臨床試驗,在其資料庫中積累了2.5萬名參與者,並收集了1000萬個數據點。欲瞭解更多資訊,請訪問。

On Behalf of the Board

我謹代表董事會

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

威爾·拉斯坎,總裁兼首席執行官
Nova Mentis生命科學公司

Phone: 778-819-0244
Toll Free: 1-833-542-5323

電話:778-819-0244
免費電話:1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

推特:@novamentislsc
Instagram:@novamentislsc
臉書:@novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新聞稿包含構成“前瞻性陳述”的陳述。此類前瞻性表述涉及已知和未知的風險、不確定性和其他因素,可能導致Nova Mentis生命科學公司的實際結果、業績或成就或行業發展與此類前瞻性表述明示或暗示的預期結果、業績或成就大不相同。前瞻性陳述是指不是歷史事實的陳述,通常但並非總是由“預期”、“計劃”、“預期”、“相信”、“打算”、“估計”、“專案”、“潛在”和類似的表述,或事件或條件“將”、“將”、“可能”、“可能”或“應該”發生。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論